Clinical and Biological Characteristics of 25 AML-M0 Patients
| . | αMPO . | Sex . | Age (yr) . | CD7 . | TdT . | CD34 . | HLA-DR . | CD13 . | CD33 . | CD15 . | CD11b . | CD11c . | CD14 . | MDR . | C-kit . | LyAg . | CD4 . | Karyotype . | Response . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DPM | + | F | 81 | − | + | + | + | + | + | − | + | + | − | + | + | − | − | NT | RD |
| PE | + | F | 60 | − | + | + | + | + | − | − | − | − | − | − | + | − | + | 46XX* | RD† |
| DPG | + | M | 53 | − | − | + | + | + | + | − | + | − | + | NT | NT | − | NT | NT | RD |
| PG | + | F | 42 | + | + | + | + | − | − | + | NT | NT | − | NT | NT | − | NT | 46XX, t(6; 11), del(5) | RD† |
| ZG | + | F | 70 | − | − | + | + | − | − | − | NT | NT | − | NT | NT | − | NT | Complex‡ | RD |
| GA | + | F | 67 | − | − | + | + | − | + | − | NT | NT | − | NT | NT | − | NT | 46XX, +13, +19 | RD |
| DVS | + | F | 27 | + | + | + | + | + | − | − | − | NT | − | NT | NT | 5 | NT | Complexρ | CR/Re |
| GM | + | M | 61 | + | + | + | − | + | + | + | + | − | − | NT | NT | 19 | NT | Complex2-155 | RD |
| RG | + | M | 62 | − | − | + | + | + | − | − | − | NT | − | NT | NT | − | NT | 47XY, +8 | CR/Re |
| LF | + | M | 44 | − | + | + | + | − | + | − | − | NT | − | NT | NT | 19 | NT | 47XY, +4 | RD |
| FM | + | F | 52 | + | − | + | + | + | + | − | + | + | + | + | NT | 2,5 | NT | Complex‡ | RD† |
| MR | + | M | 40 | + | + | + | − | + | + | − | − | + | − | + | NT | 2 | − | Complex‡ | RD |
| BE | + | F | 54 | + | − | + | + | + | + | + | − | + | − | + | NT | 10 | − | 47XX, +8 | RD |
| TP | + | F | 64 | − | + | + | + | − | − | − | − | − | − | − | NT | − | − | Complex2-154 | RD |
| CA | + | M | 39 | − | + | + | + | − | + | − | + | − | − | + | NT | − | − | NT* | RD |
| UA | + | F | 73 | − | + | + | + | + | + | + | + | + | + | − | + | − | − | Complex*,2-167 | RD |
| BV | + | M | 59 | − | + | + | + | + | − | − | + | − | − | + | − | − | + | 46XY* | RD† |
| CR | + | M | 60 | − | − | + | + | − | + | − | + | − | − | − | − | − | − | 47XY, +4* | CR |
| CD | + | M | 73 | + | − | + | − | + | + | − | − | − | + | − | + | − | + | 45X0, −Y* | RD |
| GA | + | M | 37 | − | + | + | + | + | + | − | − | + | + | − | + | − | − | 46XY* | CR/Re2-160 |
| PL | + | F | 64 | − | + | + | + | + | + | − | NT | − | − | − | + | − | − | Complex*,2-164 | RD |
| PG | + | M | 78 | − | + | − | + | + | + | − | − | − | + | − | − | 2,10 | + | 46XY* | CR/Re2-160 |
| PM | + | F | 75 | − | + | + | + | + | + | + | − | − | + | − | − | − | − | NT | RD |
| CG | + | F | 46 | + | + | + | + | − | − | − | − | − | − | NT | + | − | + | NT* | CR |
| GCG | + | M | 44 | − | + | + | + | + | + | − | − | − | − | − | − | 19,10 | − | NT* | CR/Re |
| . | αMPO . | Sex . | Age (yr) . | CD7 . | TdT . | CD34 . | HLA-DR . | CD13 . | CD33 . | CD15 . | CD11b . | CD11c . | CD14 . | MDR . | C-kit . | LyAg . | CD4 . | Karyotype . | Response . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DPM | + | F | 81 | − | + | + | + | + | + | − | + | + | − | + | + | − | − | NT | RD |
| PE | + | F | 60 | − | + | + | + | + | − | − | − | − | − | − | + | − | + | 46XX* | RD† |
| DPG | + | M | 53 | − | − | + | + | + | + | − | + | − | + | NT | NT | − | NT | NT | RD |
| PG | + | F | 42 | + | + | + | + | − | − | + | NT | NT | − | NT | NT | − | NT | 46XX, t(6; 11), del(5) | RD† |
| ZG | + | F | 70 | − | − | + | + | − | − | − | NT | NT | − | NT | NT | − | NT | Complex‡ | RD |
| GA | + | F | 67 | − | − | + | + | − | + | − | NT | NT | − | NT | NT | − | NT | 46XX, +13, +19 | RD |
| DVS | + | F | 27 | + | + | + | + | + | − | − | − | NT | − | NT | NT | 5 | NT | Complexρ | CR/Re |
| GM | + | M | 61 | + | + | + | − | + | + | + | + | − | − | NT | NT | 19 | NT | Complex2-155 | RD |
| RG | + | M | 62 | − | − | + | + | + | − | − | − | NT | − | NT | NT | − | NT | 47XY, +8 | CR/Re |
| LF | + | M | 44 | − | + | + | + | − | + | − | − | NT | − | NT | NT | 19 | NT | 47XY, +4 | RD |
| FM | + | F | 52 | + | − | + | + | + | + | − | + | + | + | + | NT | 2,5 | NT | Complex‡ | RD† |
| MR | + | M | 40 | + | + | + | − | + | + | − | − | + | − | + | NT | 2 | − | Complex‡ | RD |
| BE | + | F | 54 | + | − | + | + | + | + | + | − | + | − | + | NT | 10 | − | 47XX, +8 | RD |
| TP | + | F | 64 | − | + | + | + | − | − | − | − | − | − | − | NT | − | − | Complex2-154 | RD |
| CA | + | M | 39 | − | + | + | + | − | + | − | + | − | − | + | NT | − | − | NT* | RD |
| UA | + | F | 73 | − | + | + | + | + | + | + | + | + | + | − | + | − | − | Complex*,2-167 | RD |
| BV | + | M | 59 | − | + | + | + | + | − | − | + | − | − | + | − | − | + | 46XY* | RD† |
| CR | + | M | 60 | − | − | + | + | − | + | − | + | − | − | − | − | − | − | 47XY, +4* | CR |
| CD | + | M | 73 | + | − | + | − | + | + | − | − | − | + | − | + | − | + | 45X0, −Y* | RD |
| GA | + | M | 37 | − | + | + | + | + | + | − | − | + | + | − | + | − | − | 46XY* | CR/Re2-160 |
| PL | + | F | 64 | − | + | + | + | + | + | − | NT | − | − | − | + | − | − | Complex*,2-164 | RD |
| PG | + | M | 78 | − | + | − | + | + | + | − | − | − | + | − | − | 2,10 | + | 46XY* | CR/Re2-160 |
| PM | + | F | 75 | − | + | + | + | + | + | + | − | − | + | − | − | − | − | NT | RD |
| CG | + | F | 46 | + | + | + | + | − | − | − | − | − | − | NT | + | − | + | NT* | CR |
| GCG | + | M | 44 | − | + | + | + | + | + | − | − | − | − | − | − | 19,10 | − | NT* | CR/Re |
Abbreviations: M, male; F, female; MDR, multidrug resistance; LyAg, lymphoid antigens; NT, not tested; CR, complete remission; RD, refractor disease; Re, relapse.
No bcr-abl rearrangement as assessed by FISH.
Patients who, after chemotherapy, had a short aplasia and then experienced a leukemic regrowth with M4/M5 features.
Hyperdiploid (n ≥ 55).
ρ 46XX, 12p+, −2+m.
46XY, −9, −5, del(3).
48XX, −2, −21, +m1 , +m2 , +m3 , +m4 , del(7).
45XX, −7, del(5), del(6), der(12), t(3; 12), −18, +marker.
Patients who experienced a relapse with typical M4/M5 characteristics.
47XX, −3, +13, +marker, der(2), der(1), del(5q13), del(6), der(10), del(q11; q12), t(10; 17), del(12).